NEWS HIGHLIGHTSMedia Articles Related to Integrilin (Eptifibatide)
Some Cases of Acute Coronary Syndrome Can Wait a Day (CME/CE)
Source: MedPage Today Emergency Medicine [2009.09.01]
For some patients with acute coronary syndrome, immediate invasive treatment did not improve outcomes more than waiting till the next day, a new study found.
Published Studies Related to Integrilin (Eptifibatide)
Early versus delayed, provisional eptifibatide in acute coronary syndromes. [2009.05.21]
BACKGROUND: Glycoprotein IIb/IIIa inhibitors are indicated in patients with acute coronary syndromes who are undergoing an invasive procedure. The optimal timing of the initiation of such therapy is unknown... CONCLUSIONS: In patients who had acute coronary syndromes without ST-segment elevation, the use of eptifibatide 12 hours or more before angiography was not superior to the provisional use of eptifibatide after angiography. The early use of eptifibatide was associated with an increased risk of non-life-threatening bleeding and need for transfusion. (ClinicalTrials.gov number, NCT00089895.) 2009 Massachusetts Medical Society
Abbreviated infusion of eptifibatide after successful coronary intervention The BRIEF-PCI (Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention) randomized trial. [2009.03.10]
OBJECTIVES: The purpose of this study was to assess whether the early discontinuation of eptifibatide infusion in nonemergent percutaneous coronary intervention (PCI) is associated with a higher frequency of periprocedural ischemic myonecrosis. BACKGROUND: The recommended regimen for eptifibatide is a double bolus followed by an infusion for 18 h. It is not known whether the infusion can be shortened if the PCI is uncomplicated... CONCLUSIONS: After uncomplicated PCI, eptifibatide infusion can be abbreviated safely to <2 h. It is not inferior to the standard 18-h infusion in preventing ischemic outcome, and it may be associated with less major bleeding. (Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention [BRIEF PCI]; NCT00111566).
Bivalirudin and clopidogrel with and without eptifibatide for elective stenting: effects on platelet function, thrombelastographic indexes, and their relation to periprocedural infarction results of the CLEAR PLATELETS-2 (Clopidogrel with Eptifibatide to Arrest the Reactivity of Platelets) study. [2009.02.24]
OBJECTIVES: The primary objective of this study was to compare the effect of therapy with bivalirudin alone versus bivalirudin plus eptifibatide on platelet reactivity measured by turbidometric aggregometry and thrombin-induced platelet-fibrin clot strength (TIP-FCS) measured by thrombelastography in percutaneous coronary intervention (PCI) patients. The secondary aim was to study the relation of platelet aggregation and TIP-FCS to the occurrence of periprocedural infarction. BACKGROUND: Bivalirudin is commonly administered alone to clopidogrel naive (CN) patients and to patients on maintenance clopidogrel therapy (MT) undergoing elective stenting. The effect of adding eptifibatide to bivalirudin on platelet reactivity (PR) and TIP-FCS, and their relation to periprocedural infarction in these patients are unknown... CONCLUSIONS: For elective stenting, the addition of eptifibatide to bivalirudin lowered PR to multiple agonists and the tensile strength of the TIP-FCS, 2 measurements strongly associated with periprocedural myonecrosis. Future studies of PR and TIP-FCS for elective stenting may facilitate personalized antiplatelet therapy and enhance the selection of patients for glycoprotein IIb/IIIa blockade. (Peri-Procedural Myocardial Infarction, Platelet Reactivity, Thrombin Generation, and Clot Strength: Differential Effects of Eptifibatide + Bivalirudin Versus Bivalirudin [CLEAR PLATELETS-2]; NCT00370045.
Eptifibatide does not suppress the increase of inflammatory markers in patients with non-ST-segment elevation acute coronary syndrome. [2009.02]
BACKGROUND: Platelets are involved in inflammatory reactions which play an important role in the development of atherosclerosis and its acute complications. The objective of this study was to test the ability of glycoprotein (GP) IIb-IIIa antagonist eptifibatide to suppress the increase of inflammatory markers in non-ST-segment elevation acute coronary syndrome (ACS)... CONCLUSION: Eptifibatide does not suppress elevated levels of inflammatory markers in patients with non-ST-segment elevation ACS.
The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke: the CLEAR stroke trial. [2008.12]
BACKGROUND AND PURPOSE: Multiple approaches are being studied to enhance the rate of thrombolysis for acute ischemic stroke. Treatment of myocardial infarction with a combination of a reduced-dose fibrinolytic agent and a glycoprotein (GP) IIb/IIIa receptor antagonist has been shown to improve the rate of recanalization versus fibrinolysis alone. The combined approach to lysis utilizing eptifibatide and recombinant tissue-type plasminogen activator (rt-PA) (CLEAR) stroke trial assessed the safety of treating acute ischemic stroke patients within 3 hours of symptom onset with this combination... CONCLUSIONS: The safety of the combination of reduced-dose rt-PA plus eptifibatide justifies further dose-ranging trials in acute ischemic stroke.
Clinical Trials Related to Integrilin (Eptifibatide)
Combined Approach to Lysis Utilizing Eptifibatide and rt-PA in Acute Ischemic Stroke (CLEAR Stroke) Trial [Completed]
The purpose of this study is determine the effects of using of a combination of two
drugs--integrilin (eptifibatide) and activase (recombinant tissue plasminogen activator,
rt-PA, or recombinant t-PA)--to dissolve blood clots in patients who have a stroke.
EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome (Study P03684AM2) [Recruiting]
The purpose of this study is to see if early INTEGRILIN® (eptifibatide) therapy in patients
with non-ST-segment elevation acute coronary syndrome (ACS) reduces the occurence of death,
heart attack and urgent cardiac intervention (surgery) compared to placebo.
Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke [Recruiting]
The primary goal of this trial is to determine if individuals with acute ischemic stroke
treated with a medium dose of IV rt-PA plus IV eptifibatide started within 3 hours of
symptom onset are more likely to have a better outcome than individuals treated with
standard IV rt-PA alone.
A Safety Study of Eptifibatide in Patients With Sickle Cell Disease [Recruiting]
This study will evaluate the safety of eptifibatide in sickle cell patients and how well it
works during the course of painful crises. The overall hypothesis that we seek to test is
that increased platelet activation and the resultant inflammatory responses are important
contributors to the problems of sickle cell disease. Sickle cell disease has been referred
to both as a condition associated with increased risk of blood clots and increased
inflammation. A painful crisis represents the most common cli nical problem in sickle cell
disease, but the treatment of these crises remains inadequate.
INSTANT: INtegrilin Plus STenting to Avoid Myocardial Necrosis Trial [Recruiting]
Randomized, blind controlled, Multicenter, spontaneous, prospective trial, roughly 20
enrolling centers in Italy, placebo and active drug supply given by GlaxoSmithKline (GSK).
The Objective of the trial is compare the efficacy and, secondarily, the safety and
effectiveness of pre-procedural use of the Gp IIb/IIIa inhibitor eptifibatide in comparison
to placebo in patients with diffuse CAD undergoing multiple DES implantation.
|
